/ ABT


Abbott (ABT) Stock Sinks Despite EPS Match as Revenue Miss Sparks Selloff
/ Earnings, Market Analysis

Abbott (ABT) Stock Sinks Despite EPS Match as Revenue Miss Sparks Selloff

Abbott stock fell more than 7% in premarket trading after the company missed on Q4 revenue and gave a weaker Q1 2026 outlook, even with earnings at $1.50 per ...

January 22, 2026
Exact Sciences Spikes After Abbott Reveals Massive $23B Buyout Agreement

Exact Sciences Spikes After Abbott Reveals Massive $23B Buyout Agreement

Exact Sciences surged more than 17% premarket after Abbott announced a $23 billion buyout, adding Cologuard and Oncotype DX to its diagnostics lineup.

November 20, 2025
Abbott Laboratories Reports Strong First Quarter Results, Maintains Positive Outlook

Abbott Laboratories Reports Strong First Quarter Results, Maintains Positive Outlook

Abbott Laboratories reported a strong start to 2025 with significant growth in sales and EPS, exceeding market expectations.

April 16, 2025
Abbott Reports Strong Third-Quarter Performance with a 4.9% Increase in Worldwide Sales

Abbott Reports Strong Third-Quarter Performance with a 4.9% Increase in Worldwide Sales

Abbott Laboratories reported a strong third-quarter performance in 2024.

October 16, 2024
Abbott Laboratories Reports Strong Q2, Beating EPS and Revenue Forecasts

Abbott Laboratories Reports Strong Q2, Beating EPS and Revenue Forecasts

Abbott Laboratories (NYSE: ABT) reported sales of $10.4 billion in the second quarter of 2024, reflecting a 4.0% increase from the same period last year.

July 18, 2024